Table 3

The relationship between clinico-pathological characteristics of patients with ER negative primary operable invasive ductal breast cancer and cancer- specific survival
    Univariate survival analysis     Multivariate survival analysis
     Cancer-specific survival      Cancer-specific survival
   Hazard ratio P-value    Hazard ratio P-value
    (95% CI)     (95% CI)
Age (<50/>50 years) 0.78 (0.42-1.47 0.448
Size (≤20/21-50/>50 mm) 2.19 (1.14-4.22) 0.018 0.116
Grade (I/II/III) 1.30 (0.63-2.72) 0.478
Involved lymph node (0/1-3/>3) 1.85 (1.24-2.66) 0.001 1.71 (1.17-2.50) 0.006
Progesterone -receptor status (PR-/PR+) 0.05 (0.00-22.73) 0.330
HER-2 status (HER-2 -/HER-2+) 1.26 (0.66-2.41) 0.489
Ki-67 status (Low Ki-67/High Ki-67) 1.48 (0.70-3.11) 0.305
LVI (Absent/Present) 2.14 (1.08-4.22) 0.029 0.428
MVD (CD34+) (tertiles 1, 2, 3) 1.62 (1.08-2.44) 0.021 0.130
Loco-regional treatment (Lumpectomy + radiotherapy/mastectomy + radiotherapy) 3.27 (1.44-7.42) 0.005 2.64 (1.14-6.09) 0.023
Systemic treatment (ER-based treatment) (hormonal/hormonal + chemotherapy/chemotherapy/none) 1.00 (0.70-1.42) 1.00

Mohammed et al.

Mohammed et al. BMC Clinical Pathology 2013 13:31   doi:10.1186/1472-6890-13-31

Open Data